MediPharm Labs Corp. (“
MediPharm Labs” or the
“
Company”) (TSXV: LABS) continues to build
momentum towards its goal of becoming a global leader in
pharmaceutical-grade cannabis concentrates, by adding to its
existing management strength. MediPharm Labs is pleased to welcome
pharmaceutical industry veteran David Mayers as the Company’s newly
appointed Chief Operating Officer, and top cannabis compliance
professional Anuja Siwakoti as the Company’s newly appointed
Director of Global Regulatory and Scientific Affairs. These two
senior team members will play critical roles in leading MediPharm
Labs’ assertive growth plans in Canada and into international
markets, where cannabis is federally legal.
“David and Anuja reflect the already high level
of expertise and professionalism of our senior management team”
says Pat McCutcheon, President and CEO of MediPharm Labs. “Our
vision of international leadership in pharma-quality cannabis
concentrates and isolates requires this elevated standard of
qualifications. We continue building strength to meet our
goals.”
New Senior Leadership
David Mayers brings over 28 years of
pharmaceutical leadership in large multinational firms and small
privately held organizations, with extensive experience in
corporate strategy and oversight, research and development
(“R&D”), quality, lean sigma, production,
supply chain, procurement, information technology, finance, product
development, product launch, facility expansion, security and the
management of controlled substances. Starting his career as a
chemist for SmithKline Beecham (now GlaxoSmithKline), David
progressed through roles of increasing responsibility for Taro
Pharmaceutical Industries Ltd., Merck KGaA, Apotex Inc. and
later Purdue Pharma (Canada). Most recently, David served as the
Chief Operating Officer and member of the Board of Directors for
Impopharma Inc., a pharmaceutical company specializing in the
development and launch of pulmonary and nasal inhalation
pharmaceutical products. In his role at Impopharma Inc., David led
a turn-around of the company’s R&D programs and facilitated its
acquisition. David received his Hons. B.Sc. in Biological Science
from the University of Guelph and an MBA from the Rotman School of
Business, University of Toronto.
Anuja Siwakoti has 8 years of experience in
cannabis research, academia and work in the regulated cannabis
industry in Canada. Most recently, Anuja worked as a Senior
Quality/Regulatory Consultant at Cannabis Compliance Inc., global
cannabis consulting firm. In that role, she provided quality and
regulatory consulting services to over 50 clients, assisting with
operational gap assessment and GPP/GMP audits, guiding close to one
dozen clients with licence receipt from Health Canada, and
navigating through the cannabis regulatory jurisdiction of multiple
countries/US states. Anuja previously worked for two and a half
years at Aphria Inc., one of Canada’s leading LPs, in a senior role
in the Quality Department. She has spoken at numerous scientific
conferences and been published in peer-reviewed scientific
journals. Anuja holds a Masters degree in Medical Sciences Program
from McMaster University.
Operational Expertise
MediPharm Labs has successfully established a
team with industry leading expertise in the production of
pharmaceutical-grade cannabis concentrates. Under the leadership of
our newly appointed Chief Operating Officer, David Mayers, and with
the guidance and discipline of our Director of Quality Control and
Assurance, Dr. Chris Talpas, MediPharm has developed proprietary
methodologies and operational efficiencies which have been
leveraged to build a library of purified concentrates and
distillates.
The Company’s dynamic production has been
achieved through the operation of two production shifts daily, run
by approximately 20 production technicians. Operations are led by
sector specialists with deep expertise in cannabis extraction,
complemented by 10+ years of pharmaceutical production experience
to GMP standards. Adjunct cannabis consultants provide additional
knowledge from their home markets of California (legal adult-use
since Jan 2018 with 150 allowable products) and from the United
Kingdom with 20+ years chromatophary expertise.
A first-mover in cannabis extraction and
purification in Canada, MediPharm Labs has invested in an expert
team, customized state-of-the-art technology, proprietary
methodologies and purpose-built facilities to deliver
pharmaceutical-grade and precisely dosable cannabis oils and
cannabis concentrates for advanced derivative products. Purified
cannabis concentrates have emerged as a preferred basis for
consumption and are also the critical elements for isolate and
infused products for both the medical and adult use markets where
legal globally. MediPharm Labs is in active conversations regarding
the importing and exporting of medical cannabis where federally
permissible. Anuja Siwakoti, as the Director of Global Regulatory
and Scientific Affairs will assist in advancing MediPharm’s global
expansion.
About MediPharm Labs Corp.
MediPharm Labs, through its subsidiary, is a
pioneer in the cannabis industry and has the distinction of being
the first company in Canada to become a licensed producer for
cannabis oil production under the Access to Cannabis for Medical
Purposes Regulations (ACMPR) without first receiving a cannabis
cultivation licence. This expert focus on cannabis concentrates
from our cGMP (current Good Manufacturing Practices) and ISO
standard clean rooms and critical environments laboratory, allows
MediPharm Labs to work with its established, Health Canada-approved
cultivation partners to produce pharmaceutical-grade cannabis oil
with a competitive advantage. MediPharm Labs is research-driven and
focused on downstream secondary extraction methodology,
distillation, and cannabinoid isolation and purification. MediPharm
Labs, through its subsidiary, provides B2B contract processing of
cannabis to Canadian authorized licensed producers and appropriate
international growers, supplying integrity-assured cannabis oil to
qualified companies for sale under their own brand. In addition,
MediPharm Labs will supply raw materials, formulations, processing
and packaging for the creation of ready-to-sell advanced derivative
products. Through its subsidiary, MediPharm Labs Australia Pty.
Ltd., MediPharm Labs has also completed its application process
with the federal Office of Drug Control to extract and import
medical cannabis products in Australia.
Further Information
For additional information, please see the Company’s website at
www.medipharmlabs.com or contact:
Pat
McCutcheon, CEO and President of MediPharm Labs |
Phone: |
|
705-719-7425 ext.
216 |
Email: |
|
investors@medipharmlabs.com |
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING INFORMATION
This news release contains “forward-looking
information” and “forward-looking statements” (collectively,
“forward-looking statements”) within the meaning of the applicable
Canadian securities legislation. All statements, other than
statements of historical fact, are forward-looking statements and
are based on expectations, estimates and projections as at the date
of this news release. Any statement that involves discussions with
respect to predictions, expectations, beliefs, plans, projections,
objectives, assumptions, future events or performance (often but
not always using phrases such as “expects”, or “does not expect”,
“is expected”, “anticipates” or “does not anticipate”, “plans”,
“budget”, “scheduled”, “forecasts”, “estimates”, “believes” or
“intends” or variations of such words and phrases or stating that
certain actions, events or results “may” or “could”, “would”,
“might” or “will” be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking
statements. In this news release, forward-looking statements
relate, among other things, future growth and expansion goals.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable, are
subject to known and unknown risks, uncertainties, and other
factors which may cause the actual results and future events to
differ materially from those expressed or implied by such
forward-looking statements. Such factors include, but are not
limited to: general business, economic, competitive, political and
social uncertainties; and the delay or failure to receive
regulatory approvals. There can be no assurance that such
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
the forward-looking statements and information contained in this
news release. Except as required by law, the Company assumes no
obligation to update the forward-looking statements of beliefs,
opinions, projections, or other factors, should they change.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/c116acc4-fffe-4f18-9417-7f1e2c13b3ee
MediPharm Labs (TSXV:LABS)
Historical Stock Chart
From Mar 2024 to Apr 2024
MediPharm Labs (TSXV:LABS)
Historical Stock Chart
From Apr 2023 to Apr 2024